JP2019178177A5 - - Google Patents

Download PDF

Info

Publication number
JP2019178177A5
JP2019178177A5 JP2019137721A JP2019137721A JP2019178177A5 JP 2019178177 A5 JP2019178177 A5 JP 2019178177A5 JP 2019137721 A JP2019137721 A JP 2019137721A JP 2019137721 A JP2019137721 A JP 2019137721A JP 2019178177 A5 JP2019178177 A5 JP 2019178177A5
Authority
JP
Japan
Prior art keywords
composition
administration
oral
continuous infusion
cangrelor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019137721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019178177A (ja
JP6840197B2 (ja
Filing date
Publication date
Priority claimed from US13/792,056 external-priority patent/US9427448B2/en
Application filed filed Critical
Publication of JP2019178177A publication Critical patent/JP2019178177A/ja
Publication of JP2019178177A5 publication Critical patent/JP2019178177A5/ja
Application granted granted Critical
Publication of JP6840197B2 publication Critical patent/JP6840197B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019137721A 2013-03-09 2019-07-26 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法 Active JP6840197B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/792,056 US9427448B2 (en) 2009-11-11 2013-03-09 Methods of treating, reducing the incidence of, and/or preventing ischemic events
US13/792,056 2013-03-09
US201361815735P 2013-04-25 2013-04-25
US61/815,735 2013-04-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017197488A Division JP2018002739A (ja) 2013-03-09 2017-10-11 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法

Publications (3)

Publication Number Publication Date
JP2019178177A JP2019178177A (ja) 2019-10-17
JP2019178177A5 true JP2019178177A5 (https=) 2019-12-26
JP6840197B2 JP6840197B2 (ja) 2021-03-10

Family

ID=51537409

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015561314A Active JP6247708B2 (ja) 2013-03-09 2013-05-29 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法
JP2017197488A Withdrawn JP2018002739A (ja) 2013-03-09 2017-10-11 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法
JP2019137721A Active JP6840197B2 (ja) 2013-03-09 2019-07-26 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015561314A Active JP6247708B2 (ja) 2013-03-09 2013-05-29 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法
JP2017197488A Withdrawn JP2018002739A (ja) 2013-03-09 2017-10-11 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法

Country Status (10)

Country Link
EP (2) EP3978002A1 (https=)
JP (3) JP6247708B2 (https=)
CN (2) CN115120606A (https=)
AU (1) AU2013381855B2 (https=)
BR (1) BR112015022070B1 (https=)
CA (1) CA2904523C (https=)
EA (1) EA034550B1 (https=)
ES (1) ES2904256T3 (https=)
PL (1) PL2964233T3 (https=)
WO (1) WO2014143107A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022070B1 (pt) * 2013-03-09 2022-01-18 Chiesi Farmaceutici S.P.A. Uso de cangrelor
US11260071B2 (en) 2017-06-23 2022-03-01 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281309B6 (sk) 1993-02-10 2001-02-12 Astra Pharmaceuticals Limited N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov
ID21635A (id) 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
WO2009140092A1 (en) * 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20100297675A1 (en) * 2008-11-24 2010-11-25 Huayun Deng Substrate and method for culturing breast cells
RU2011132125A (ru) * 2008-12-30 2013-02-10 Тромбологик Апс Способы идентификации критических пациентов с повышенным риском развития органной недостаточности и соединения для их лечения
EP2443120B1 (en) * 2009-06-16 2016-11-02 RSPR Pharma AB Crystalline form of pemirolast
PT2498731T (pt) * 2009-11-11 2020-02-21 Chiesi Farm Spa Métodos de tratamento ou prevenção de uma trombose de endoprótese
BR112015022070B1 (pt) * 2013-03-09 2022-01-18 Chiesi Farmaceutici S.P.A. Uso de cangrelor

Similar Documents

Publication Publication Date Title
JP2023088944A5 (https=)
EP0893998B2 (en) Colonic delivery of nicotine to treat inflammatory bowel disease
JP2025020134A5 (https=)
US11607389B2 (en) Delayed release deferiprone tablets and methods of using the same
JP2019501881A5 (https=)
JP2019178177A5 (https=)
CN113274384B (zh) 驴食草酚在制备防治溃疡性结肠炎的药物中的应用及其药物
JP2025148449A5 (https=)
JP2020510043A5 (https=)
JP2016505050A5 (https=)
JP2022035920A5 (https=)
JP2019509309A5 (https=)
JP2016510738A5 (https=)
WO2020183020A1 (en) Capsid assembly modulator solid formulation
JP7376679B2 (ja) Hbv感染の処置のためのeyp001とifnの相乗効果
WO2018004498A1 (en) Nsaid and h2 receptor antagonist combinations for the treatment of pain and inflammation
TW201806599A (zh) 用於快速開始抗抑鬱作用之給藥方案
JP2012025734A (ja) 骨髄異形性症候群を治療するための組成物および方法
JPWO2021048280A5 (https=)
HK40066536B (en) Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection
HK40066536A (en) Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection
JPWO2021150559A5 (https=)
JPWO2021005129A5 (https=)
JPWO2021127308A5 (https=)
JPWO2022035752A5 (https=)